The was developed as a 21-item patient-reported measure of appetite and eating behaviors relevant to obesity treatment.
Evidence
This questionnaire development and content-evaluation study used literature review, 40 phase 2 trial exit interviews, 3 clinician interviews, and 24 USA-based cognitive interviews.
Caveat
The abstract supports content clarity and relevance, but does not report psychometric validation, responsiveness, or performance in broader populations.
Simplified
INTRODUCTION: Obesity management medications can reduce body weight and have an impact on patients' appetite and eating behaviors. Existing (PRO) measures do not fully capture appetite and eating behavior concepts relevant to individuals living with obesity, including those receiving treatment. Here we describe the development and content evaluation of the (EBAQ), a new PRO measure to enable a comprehensive assessment of appetite and eating behaviors which are important to individuals living with obesity.
METHODS: The EBAQ was developed on the basis of findings from a targeted literature review, findings from exit interviews with participants (N = 40) in a phase 2 trial for retatrutide (NCT04881760), and interviews with clinicians specializing in obesity medicine (N = 3). Cognitive interviews were conducted with USA-based adults with obesity or with overweight and ≥ 1 obesity-related complications (hypertension, dyslipidemia, cardiovascular disease) (N = 24) to evaluate the content of the EBAQ.
RESULTS: All 24 cognitive interview participants reported a positive overall impression of the EBAQ and that they understood the instructions and recall period. Most participants (n = 23, 96%) found the response options to be clear and appropriate. Items in the EBAQ were considered clear and relevant by the participants. The 21-item EBAQ is a new PRO measure with three domains to evaluate eight appetite and eating behavior concepts relevant to obesity and which may change with obesity treatment.
CONCLUSION: The EBAQ may be used in clinical trials, clinical practice, or observational research to evaluate the impact of obesity and the effect of obesity treatment on appetite and eating behaviors.
Key numbers
24
Cognitive Interview Participants
Participants included adults with obesity or overweight and complications.
21
Items
The measure evaluates three domains relevant to obesity.
96%
Positive Feedback Rate
Participants found the response options clear and appropriate.
Full Text
We can’t show the full text here under this license.
Declarations. Conflict of interest: Chisom Kanu, Iris Goetz, Lisa Mary Neff, and Kristina Secnik Boye are employees and shareholders of Eli Lilly and Company, which funded this study. Claudine Clucas, Hayley Karn, Anne Skalicky, and Ashley Samuelson are current employees of Evidera-PPD, which was paid by Eli Lilly and Company to conduct this study. The Eating Behavior and Appetite Questionnaire (EBAQ) is copyrighted by Eli Lilly and Company and is free for use once permission is obtained. For permission to reproduce or use the EBAQ, contact copyright@lilly.com. Ethical Approval: This study was approved by Salus IRB (Austin, Texas, USA) and conducted in accordance with the Declaration of Helsinki, Good Pharmacoepidemiology Practices, International Society for Pharmacoeconomics and Outcomes Research PRO Good Practice Task Force procedures, International Society of Quality of Life Research Translation and Cultural Adaptation Special Interest Group good practices, and all applicable laws and regulations in the USA. All participants provided written informed consent before the interviews.
